Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.
Strategic intelligence for a fiercely competitive marketplace. In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. Deallus look at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.
CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.
From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.
Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace. In this white paper we explore the digitization trend currently infiltrating healthcare and delve into the implications of digital health on patients, payers, and pharma itself. We take stock of the current landscape, discuss likely future trends, and explore how strategic intelligence can help answer key questions for the healthcare industry in the face of so much digital innovation.
Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States. Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.
